Replies to post #17312 on Greater Cannabis Company Inc (GCAN)

[29YEARINVESTOR]

Agree The 10k says it all! LOL! Just like the Buyers and Volume! LOL!
No Dumping just steady accumulation! What happened was Everyone that read and understood the 10k Liked it. Plus Brazils 5th largest and 40 year old company just signed an LOI with GCAN and It caused about a 100% increase with medium Volume of less than 1 million shares on any given day last week and it has been steadily up from there. Because GCAN only has 33 million O/S With all these new deals and GCAN becoming discovered. GCAN could very well see many more 100% days.
If we look at GCAN's trading history the biggest volume day so far was a little over 10 million shares and every time GCAN gets up over a couple of million or better in volume in one day it has moved over 100% in hours even with MM's naked shorting half or better of that volume:
Sep 19 2018
change +166.49% up
Volume 2,588,518

Oct 03 2018
change +231.25% up
Volume 4,913,665

Nov 02 2018
change +111.46% up
Volume 10,574,248

https://www.gcanrx.com/our-technology.html

What makes GCAN dollars realistic compared to other cannabis stocks is it's extremely low 33 million O/S and GCAN's super Low Float along with a great Team, Quality Leadership and Name brand. Who knows how high GCAN will go. Just compare GCAN with It's extremely low 33 million O/S and super Low Float to other cannabis stocks like Aurora that have nearly 1 billion O/S. GCAN is still undiscovered by the Masses like Aurora was a few years ago when it was trading in the pennies also.
Look and Compare:
GCAN: Outstanding Shares 33 million O/S Trading in the pennies
Aurora: Outstanding Shares 958 million O/S Trading at $9.00

Allume Cosmeticos is the Real Deal and so is GCAN that will provide ALLUME the formulations to infuse pharmaceutical-grade CBD, into a new line of cosmetics, …
https://thedailyrecord.com/2019/04/12/maryland-greater-cannabis-allume-cosmeticos/
GCAN's other agreement is with iCAN and will include commercial ready formulations to meet medical and recreational market demands. Distribution and marketing rights for iCAN will include Israel, Australia, South Africa, Netherlands, South Africa, Mexico, Colombia, Panama, Germany, Austria, Switzerland, Malta, Macedonia, and Portuguese territories.